Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2025-06-12 Capital/Financing Update
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
교환사채권발행결정(종속회사의주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a South Korean company (L&C Bio) detailing the decision to issue exchangeable bonds (EB) by its subsidiary. It includes specific financial terms such as the total amount, interest rates, maturity dates, exchange ratios, and the use of proceeds. This type of disclosure regarding capital structure changes and financing activities falls under the 'Capital/Financing Update' category.
2025-06-12 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) by L&C Bio. It details the purpose of the funds, terms of the convertible bonds, conversion price adjustments, and put/call option details. This is a regulatory filing required by the Korea Exchange (KRX) for material corporate events, specifically related to capital structure changes and financing. It is not an announcement of a report (RPA) but the report itself, and it fits best under 'Share Issue/Capital Change' (SHA) as it pertains to the issuance of convertible securities that impact share capital.
2025-06-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a specific entity (Ascent-Meritz Fund 1) in a listed company (L&C Bio). This type of filing is a mandatory disclosure of significant shareholding changes and falls under the category of Major Shareholding Notification.
2025-06-10 Korean
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the conversion of debt into equity, the number of shares to be issued, and the updated listing date. This type of corporate action, involving the issuance of new shares resulting from debt conversion, falls under the category of share issues or capital changes.
2025-05-27 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from L&C Bio regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2025-05-27 Korean
주요사항보고서(제3자의전환사채매수선택권행사)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission of South Korea. It specifically details the exercise of a call option on convertible bonds (제3자의 전환사채매수선택권 행사) by the company's largest shareholder. This type of filing relates to capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2025-05-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.